Strategic Partnerships Leverage Ionis’s strong licensing model and ongoing collaborations with major players like Novartis to position co-development or licensing opportunities, particularly in neurology and cardiology where their RNA-targeted portfolio and Angelman therapy programs indicate advanced research and potential for joint ventures.

Product Launch Readiness Capitalize on recent Zanvastro launch momentum and upcoming US rollout to offer services that optimize commercialization efforts, including market access strategies, payer alignment, and launch analytics to accelerate uptake and maximize early revenue generation.

Licensing Revenue Focus Target opportunities around licensing payments and milestone-based revenue, acknowledging Ionis’s historical reliance on licensing income and one-off items; propose high-value deals that de-risk investments for Ionis while delivering scalable collaboration models.

Neurology Pipeline Position solutions tailored to neurology indications with Ionis’s leading pipeline, including biomarker development, real-time monitoring, and patient recruitment tools that can shorten trial timelines and improve data quality for RNA-targeted therapies.

Competitive Positioning Offer competitive intelligence and market trend analyses related to Angelman therapies and RNA technology space to help Ionis differentiate from Ultragenyx and Arrowhead; propose strategic partnerships or advisory services that strengthen go-to-market advantages.